Furthermore, our study highlights the ability of β-ARs antagonists in modulating both tumor growth and the induction of cancer-evoked pain, giving to these receptors unique features as promising therapeutic targets for cancer therapy and associated pain. The gene discussed is CTBP1; the disease is neoplasm.